University of Kentucky

Important Dementia Studies Continuing at UK Despite Ongoing COVID-19 Pandemic

3-Aug-2020 10:20 AM EDT, by University of Kentucky

Newswise — LEXINGTON, Ky.  (July 30, 2020) —The COVID-19 pandemic brought many things to a screeching halt and continues to impact our daily lives. However, important research at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) is continuing under extreme caution and deep dedication.

“It can’t wait,” said Dr. Greg Jicha, a neurologist at SBCoA.  

A monumental study in the field of dementia research is set to get underway in the coming weeks at UK. Researchers will be looking at a medication that recently received experimental approval from The United States Food and Drug Administration and its impact on the newly characterized form of dementia known as LATE. The disease was named and popularized about one year ago by an international working group led by Dr. Peter Nelson, the senior neuropathologist at SBCoA.

LATE is a disease with symptoms similar to Alzheimer’s disease. Those symptoms are referred to as “dementia,” but are caused by different underlying processes in the brain. LATE is important because it affects millions of people – approximately 40% of people over the age of 85. 

So how was it recognized?  Researchers around the world noticed that a large number of people who died in advanced age had symptoms of dementia without the telltale features of Alzheimer’s disease (“plaques and tangles”) in their brains at autopsy.  Emerging research indicated that the protein TDP-43 contributed to that phenomenon. 

"Dozens of different viruses and bacteria can cause pneumonia," Nelson said. "So why would we think there is just one cause of dementia?"

Jicha says this is an example of a true partnership between Nelson’s science and direct care in the development of medicines.

“While everyone else around the globe is still trying to understand what this diagnosis is, UK is already moving forward to treat this disease," he said. "That is something that is not happening anywhere else in the world.”

Both Jicha and Nelson reiterate that they are not trying to downplay COVID-19. However, through their work, they are constantly reminded the risk of death from dementia is 100%.

“The thing that is really going to take our society down is dementia,” said Nelson. “People are very aggressive about treating cancer. There has been a less interventional approach to dementia, and I think that needs to change.”

So how do they plan to safely conduct a trial in the midst of COVID-19 when it involves participants who are at the highest risk to catch the disease and have the most serious consequences?

“That is a real barrier and that’s really pushed us to create the safest place as possible for protection against COVID-19 … because our research participants deserve that,” said Jicha.

SBCoA has worked with every different component of safety regarding COVID-19. Additionally, they are testing all research participants before they can enter the clinic as well as all staff members that participants could potentially come in contact with. “We aren’t only testing the staff in our clinic but also UK nurses, the people that run the MRIs … literally anybody that our people come in contact with so that we can guarantee that all have been COVID tested and are negative,” said Jicha.

Due to the success in reopening the clinic and keeping research going, Jicha has actually presented both nationally and internationally on the procedures at SBCoA. He says because of their efforts, they can be confident that the chances of someone catching COVID-19 in the clinic are extremely low. They are hopeful that the measures put in place, along with the extreme care and caution being exemplified by everyone at SBCoA, will help ease any worries of participants who are helping with this newest research.,

The upcoming study will look at participants with mild memory problems who are ages 75 and older. Jicha says they will be screened for Alzheimer’s disease, and if they do not have the Alzheimer’s plaques on their brain, then it is highly likely that they have LATE. The participants will be treated with the experimental drug for a two-year period. Nelson says they are hoping to get more participants who are in advanced aging but are not experiencing extreme cognitive issues,

“Those are the people we can prevent from declining,” he said.

Jicha says thanks to his colleague’s science, the medication they are studying is designed not to help manage the dementia symptoms but instead actually modify the gene that causes the disease to progress. “This could potentially cure the disease versus just being a band-aid for the symptoms,” he said. The study is being funded by a grant from the National Institute on Aging.

Nelson says this work of transitioning his science directly into a potential treatment, all in one location, solidifies his decision years ago to come to UK.

“We know we have the best horses … we love that! We know we have the best basketball team … we love that! We know we have the best bourbon … we love that!" Nelson said. "But what a lot of people don’t know is that we have this gem. The number one place for involving research participants in trials for dementia is the University of Kentucky.”

It is thanks to being part of that world-class center that Jicha and Nelson are able to move this cutting-edge research forward.

“The discovery doesn’t stop here. As with all good science, every question that is answered takes us forward,” said Jicha.


If you are interested in learning more about this study, contact the Sanders-Brown Center on Aging at 859-323-5550.


Filters close

Showing results

110 of 3327
Newswise: How to Keep Children Safe from COVID-19 this Fall
Released: 18-Sep-2020 4:15 PM EDT
How to Keep Children Safe from COVID-19 this Fall
Rush University Medical Center

With the new school year started and autumn approaching, Colleen Nash, MD, MPH, Rush University Medical Center, pediatric infectious disease specialist, answers questions parents may have about keeping children safe from COVID, social distancing in the classroom and celebrating Halloween.

Released: 18-Sep-2020 4:05 PM EDT
Claims circulating on social media stating that the common cold or flu can be mistaken for COVID-19 are misleading

The claims rely on the faulty assumption that there is no method to distinguish COVID-19 from the common cold and the flu.

Released: 18-Sep-2020 3:35 PM EDT
After developing CRISPR test, UConn researchers validate clinical feasibility for COVID-19 testing
University of Connecticut

In March, researchers in the Department of Biomedical Engineering-- a shared department in the schools of Dental Medicine, Medicine, and Engineering--began to develop a new, low-cost, CRISPR-based diagnostic platform to detect infectious diseases, including HIV virus, the novel coronavirus (SARS-CoV-2).

Newswise:Video Embedded blowin-in-the-wind
Released: 18-Sep-2020 3:10 PM EDT
Blowin' in the wind
University of Utah

University of Utah chemical engineers have conducted an air flow study of the venue that the Utah Symphony performs in to determine the best ways to mitigate the spread of COVID-19 through the emissions of wind instrument players.

Newswise: holman1_toned-1-768x512.jpg
Released: 18-Sep-2020 2:50 PM EDT
Study links rising stress, depression in U.S. to pandemic-related losses, media consumption
University of California, Irvine

Irvine, Calif., Sept. 18, 2020 – Experiencing multiple stressors triggered by the COVID-19 pandemic – such as unemployment – and COVID-19-related media consumption are directly linked to rising acute stress and depressive symptoms across the U.S., according to a groundbreaking University of California, Irvine study. The report appears in Science Advances, published by the American Association for the Advancement of Science.

Newswise: 243389_web.jpg
Released: 18-Sep-2020 10:55 AM EDT
Potential new drug to mitigate SARS-CoV-2 infection consequences
University of Malaga

Scientists from the Department of Cell Biology of the University of Malaga (UMA) and the Andalusian Centre for Nanomedicine and Biotechnology (BIONAND) have made progress in finding new rapid implementation therapies to combat the COVID-19 pandemic, identifying a new drug that could prevent or mitigate the consequences derived from SARS-CoV-2 infection.

Newswise: 243400_web.jpg
Released: 18-Sep-2020 10:40 AM EDT
Most homemade masks are doing a great job, even when we sneeze, study finds
University of Illinois at Urbana-Champaign

Studies indicate that homemade masks help combat the spread of viruses like COVID-19 when combined with frequent hand-washing and physical distancing.

access_time Embargo lifts in 2 days
Embargo will expire: 23-Sep-2020 8:00 AM EDT Released to reporters: 18-Sep-2020 10:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 23-Sep-2020 8:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 18-Sep-2020 8:30 AM EDT
Immunotherapy Drug Development Pipeline Continues Significant Growth in 2020 Despite Global Pandemic Impact
Cancer Research Institute

Despite the impact of the COVID-19 pandemic across the globe, there has been a resurgence of interest in immuno-oncology (I-O) preclinical and clinical development, bringing hope to cancer patients and physicians who treat them.

Showing results

110 of 3327